Cure My Disease

Don't miss your cure!

 Log in / Sign up

New chemo cocktail aims to boost stomach cancer cure rates

NCT ID NCT03773367

Ongoing ⭐️ CURE ⭐️ Sponsor: Lund University Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 30 times

Summary

This study tests whether adding a third chemotherapy drug (irinotecan) to the standard two-drug regimen before and after surgery can improve outcomes for people with resectable stomach or gastroesophageal junction cancer. About 60 adults with early-stage, operable cancer will receive 4 cycles of the three-drug combo before surgery and 4 cycles after. The goal is to see if this stronger approach leads to better tumor shrinkage and higher cure rates.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centrallasarettet i Växjö

    Vaxjo, 352 34, Sweden

  • Karolinska University Hospital

    Stockholm, 141 86, Sweden

  • Lund University Hospital

    Lund, 221 85, Sweden

  • Oslo University Hospital, Ullevål Hospital

    Oslo, 0450, Norway

Conditions

Explore the condition pages connected to this study.

RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA